Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans

Journal of Hypertension

Volumn 28, Issue 3, 2010, Pages 520-526

  Coltamai, Lionel ^a   Maillard, Marc ^a   Simon, Alexandra ^a   Vogt, Bruno ^a   Burnier, Michel ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Angiotensin II; Blood pressure; Diuretics; Human; Renal; Vascular

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; OLMESARTAN; VALSARTAN;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; INFUSION; KIDNEY BLOOD FLOW; KIDNEY BLOOD VESSEL; KIDNEY PLASMA FLOW; KIDNEY TUBULE FUNCTION; MALE; NORMAL HUMAN; OBSERVATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SINGLE BLIND PROCEDURE; SODIUM URINE LEVEL; TREATMENT DURATION; URINE VOLUME;

EID: 77149136418     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283346be1     Document Type: Article

References (27)

1. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001; 103:904-912.
2. Forclaz A, Maillard M, Nussberger J, Brunner HR, Burnier M. Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor? Hypertension 2003; 41:31-36.
3. Maillard MP, Wurzner G, Nussberger J, Centeno C, Burnier M, Brunner HR. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. Clin Pharmacol Ther 2002; 71:68-76.
4. Mazzolai L, Maillard M, Rossat J, Nussberger J, Brunner HR, Burnier M. Angiotensin II receptor blockade in normotensive subjects: a direct comparison of three AT1 receptor antagonists. Hypertension 1999; 33:850-855.
5. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de FU, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003. (Pubitemid 34286536)
6. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878. (Pubitemid 34940826)
7. Yu C, Gong R, Rifai A, Tolbert EM, Dworkin LD. Long-term, high-dosage candesartan suppresses inflammation and injury in chronic kidney disease: nonhemodynamic renal protection. J Am Soc Nephrol 2007; 18:750-759.
8. Azizi M, Guyene TT, Chatellier G, Menard J. Pharmacological demonstration of the additive effects of angiotensin-converting enzyme inhibition and angiotensin II antagonism in sodium depleted healthy subjects. Clin Exp Hypertens 1997; 19 (5-6): 937-951.
9. Azizi M, Guyene TT, Chatellier G, Wargon M, Menard J. Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension 1997; 29:634-640.
10. Azizi M, Linhart A, Alexander J, Goldberg A, Menten J, Sweet C, et al. Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients. J Hypertens 2000; 18:1139-1147.
11. Burgess E, Muirhead N, de Cotret PR, Chiu A, Pichette V, Tobe S. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol 2009; 20:893-900.
12. Hollenberg NK, Parving HH, Viberti G, Remuzzi G, Ritter S, Zelenkofske S, et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007; 25:1921-1926.
13. Schmieder RE, Klingbeil AU, Fleischmann EH, Veelken R, Delles C. Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol 2005; 16:3038-3045.
14. Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 2005; 68:1190-1198.
15. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372:547-553.
16. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559.
17. Hou FF, Xie D, Zhang X, Chen PY, Zhang WR, Liang M, et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol 2007; 18:1889-1898.
18. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358:2433-2446.
19. Navar LG, Imig JD, Zou L, Wang CT. Intrarenal production of angiotensin II. Semin Nephrol 1997; 17:412-422.
20. Ruan X, Wagner C, Chatziantoniou C, Kurtz A, Arendshorst WJ. Regulation of angiotensin II receptor AT1 subtypes in renal afferent arterioles during chronic changes in sodium diet. J Clin Invest 1997; 99:1072-1081.
21. Pechere-Bertschi A, Nussberger J, Decosterd L, Armagnac C, Sissmann J, Bouroudian M, et al. Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients. J Hypertens 1998; 16:385-393.
22. Magnin JL, Decosterd LA, Centeno C, Burnier M, Diezi J, Biollaz J. Determination of trace lithium in biological fluids using graphite furnace atomic absorption spectrophotometry: variability of urine matrices circumvented by cation exchange solid phase extraction. Pharm Acta Helv 1996; 71:237-246.
23. Christen Y, Waeber B, Nussberger J, Porchet M, Borland RM, Lee RJ, et al. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II. Circulation 1991; 83:1333-1342.
24. Ferguson RK, Turini GA, Brunner HR, Gavras H, McKinstry DN. A specific orally active inhibitor of angiotensin-converting enzyme in man. Lancet 1977; 1:775-778.
25. Hasler C, Nussberger J, Maillard M, Forclaz A, Brunner HR, Burnier M. Sustained 24-h blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor. Clin Pharmacol Ther 2005; 78:501-507.
26. Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 2003; 63:1874-1880.
27. Vos PF, Boer P, Braam B, Koomans HA. Efficacy of intrarenal ACE-inhibition estimated from the renal response to angiotensin I and II in humans. Kidney Int 1995; 47:274-281.